Novel Multivalent mRNA Vaccines Show Promise Against MPXV and SARS-CoV-2 in Preclinical Studies
Key Insights
Two separate multivalent mRNA vaccine candidates demonstrated strong immunogenicity and safety profiles in preclinical animal studies, with the MPXV (search) vaccine providing 100% protection against viral challenge and the SARS-CoV-2 (search) vaccine showing neutralizing antibody production against multiple variants.
The MPXV (search) trivalent mRNA vaccine (AALI) targeting both IMV and EEV viral forms induced robust antibody responses with high binding affinities and generated neutralizing antibody titers of 1:900, while also activating both CD4+ and CD8+ T-cell responses.
Both vaccines showed acceptable safety profiles in toxicity studies, with the SARS-CoV-2 (search) vaccine (RGV-DO-003) demonstrating no serious adverse effects at clinical doses and the MPXV (search) vaccine showing no cytotoxicity or pathological changes in major organs.
Two groundbreaking multivalent mRNA vaccine studies have demonstrated significant promise in preclinical development, with researchers reporting robust immune responses and strong safety profiles for vaccines targeting both monkeypox virus (search) (MPXV (search)) and SARS-CoV-2 (search).
MPXV Vaccine Achieves Complete Protection in Challenge Studies
A novel trivalent mRNA vaccine targeting MPXV (search) has shown remarkable efficacy in animal studies, providing 100% protection against viral challenge across multiple strains. The vaccine, designated AALI, incorporates antigens from both the intracellular mature virion (IMV) and extracellular enveloped virion (EEV) forms of the virus, along with interferon-alpha as an adjuvant.
In challenge studies using female BALB/c mice, the AALI vaccine (search) demonstrated complete cross-protection against clade II MPXV (search) strains SZTH42 and SZTH41, as well as the vaccinia virus Tiantan strain. Vaccinated mice experienced minimal weight loss and showed no visible pathological changes in lung tissue, while control groups displayed severe alveolar damage and inflammatory infiltration.
The vaccine induced potent neutralizing antibody responses, with median neutralizing antibody titers reaching 1:900 for AALI and 1:300 for the AAL formulation without interferon-alpha. Surface plasmon resonance analysis revealed high-affinity binding to MPXV (search) antigens, with dissociation constants ranging from 2.35 × 10⁻⁹ M to 8.40 × 10⁻⁸ M for clade II MPXV antigens.
Advanced Single-Cell Analysis Reveals Immune Mechanisms
Comprehensive single-cell RNA sequencing analysis provided unprecedented insights into the vaccine's immunological mechanisms. The study revealed a significant increase in plasma cell populations in vaccinated mice, with 69 ± 6 AAL-specific, 134 ± 8 A29L (search)-specific, and 161 ± 17 A35R (search)-specific antibody-secreting cells per million detected at peak response.
The analysis identified specific B-cell and T-cell clonal expansion patterns, with unique CDR3 motifs including "YAMDY," "CARGGY," and "GYYYFDY" in immunoglobulin heavy chains. These molecular signatures suggest the development of MPXV (search)-specific immune memory that could provide long-term protection.
SARS-CoV-2 Vaccine Demonstrates Broad Variant Coverage
Separately, researchers evaluated the RGV-DO-003 mRNA vaccine (search) targeting SARS-CoV-2 (search), which showed strong neutralizing antibody production against multiple viral variants. The vaccine demonstrated efficacy against wild-type SARS-CoV-2, Omicron BA.1.1.529, and BA.5 variants in focus reduction neutralization tests.
In virus challenge studies using hACE2 transgenic mice, the vaccine group showed an average neutralizing IgG antibody titer of 342,467 ng/mL, while control groups showed no detectable neutralizing antibodies. Necropsy examination revealed significantly reduced lung pathology in vaccinated animals compared to controls.
Comprehensive Safety Profiles Support Clinical Translation
Both vaccine candidates demonstrated acceptable safety profiles across multiple toxicology studies. The SARS-CoV-2 (search) vaccine showed no mortality or significant adverse effects in single-dose and repeated-dose toxicity studies in Sprague-Dawley rats at clinical doses of 50 μg per animal.
Observed effects were primarily related to expected immune activation, including temporary increases in white blood cell counts and neutrophils, along with transient inflammation at injection sites. All changes resolved during recovery periods, with researchers noting that "the RGV-DO-003 mRNA vaccine (search) did not induce severe systemic adverse effects, indicating its potential for use in human clinical trials."
The MPXV (search) vaccine similarly showed no cytotoxicity in cell culture studies and no pathological alterations in major organs during both short-term and long-term safety evaluations. Liver and kidney function indicators remained within normal ranges across all treatment groups.
Technical Innovations Enable Enhanced Delivery
Both vaccines utilized advanced lipid nanoparticle (LNP) formulations to enhance mRNA delivery and stability. The MPXV (search) vaccine employed mannose-conjugated LNPs with approximately 95% mRNA encapsulation efficiency, while the SARS-CoV-2 (search) vaccine achieved 88.19% encapsulation efficiency with 85.80% mRNA integrity preservation.
The LNP formulations demonstrated optimal physicochemical properties, with particle sizes ranging from 100-120 nm and low polydispersity indices indicating uniform distribution. Dynamic light scattering analysis confirmed stable particle characteristics suitable for vaccine delivery.
Implications for Future Pandemic Preparedness
These findings represent significant advances in mRNA vaccine technology, particularly for emerging infectious diseases. The multivalent approach demonstrated by both vaccines could provide broader protection against viral variants and reduce the need for frequent vaccine updates.
The detailed immunological characterization, including single-cell analysis, provides valuable insights for optimizing future mRNA vaccine designs. The identification of specific immune signatures and clonal expansion patterns could inform the development of next-generation vaccines with enhanced efficacy and duration of protection.
Both research teams emphasized the need for additional studies, including evaluation in non-human primates and eventual human clinical trials, to fully establish the vaccines' safety and efficacy profiles for clinical use.